STOCK TITAN

BioStem Technologies CEO sells 14,300 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

BioStem Technologies, Inc. Chief Executive Officer, director and 10% owner Jason Matuszewski sold 14,300 common shares at $1.00 per share on November 17, 2026, to cover tax obligations connected with exercising vested options. His direct common-share holdings after the sale were 1,539,251; no Rule 10b5-1 plan was reported for the sale. The report also lists direct options covering 2,000,000 common shares at $2.00, 198,807 and 40,427 shares at $10.05, and 440,529 shares at $5.50, with expirations from October 24, 2032, through February 11, 2036.

Insider Matuszewski Jason
Role Chief Executive Officer
Sold 14,300 shs ($14K)
Share of Position Sold 0.92%
Type Security Shares Price Value
Sale Common Stock F1 14,300 $1.00 $14K
Holding Series A-1 Convertible Preferred Shares F2, F3 -- -- --
Holding Options (Right to Buy) F4 -- -- --
Holding Options (Right to Buy) F5 -- -- --
Holding Options (Right to Buy) F6 -- -- --
Holding Options (Right to Buy) F7 -- -- --
Holding Restricted Stock Units F8, F9 -- -- --
Holding Restricted Stock Units F8, F10 -- -- --
Holding Restricted Stock Units F8, F11 -- -- --
Holdings After Transaction: Common Stock — 1,539,251 shares (Direct); Series A-1 Convertible Preferred Shares — 100 shares (Direct); Options (Right to Buy) — 2,679,763 options (Direct); Restricted Stock Units — 497,411 units (Direct)
Holdings Before and After: Common Stock, 1,553,551 to 1,539,251 shares (Direct)
Footnotes (11)
  1. F1. Represents shares sold to cover the Reporting Person's tax obligation in connection with the exercise of vested options to purchase shares of the Issuer's Common Stock.
  2. F2. The Series A-1 Preferred Convertible Stock is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Preferred Stock.
  3. F3. The Series A-1 Preferred Convertible Stock has no expiration date.
  4. F4. These options are fully vested and exercisable.
  5. F5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  6. F6. These options vest according to the following schedule: 33% vested on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  7. F7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
  8. F8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  9. F9. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
  10. F10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
  11. F11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Common shares sold 14,300 shares November 17, 2026; sold to cover tax obligations connected with exercising vested options
Sale price $1.00 per share November 17, 2026
Direct common shares held after sale 1,539,251 shares After the November 17, 2026 sale
Options at $2.00 exercise price 2,000,000 underlying common shares Expire October 24, 2032
Options at $10.05 exercise price 198,807 underlying common shares Expire March 17, 2035
Options at $10.05 exercise price 40,427 underlying common shares Expire October 13, 2035
Options at $5.50 exercise price 440,529 underlying common shares Expire February 11, 2036
Series A-1 preferred shares 100 shares Convertible one-for-one into common shares at the option of a majority of preferred holders
vested options technical
"exercise of vested options to purchase shares"
Series A-1 Preferred Convertible Stock technical
"convertible in whole into shares of the Issuer's Common Stock"
one-to-one basis technical
"on a one-to-one basis at the option of a majority"
restricted stock units financial
"Each restricted stock unit represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right technical
"a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BSEM shares did CEO Jason Matuszewski sell, and at what price?

Jason Matuszewski sold 14,300 common shares at $1.00 per share on November 17, 2026, to cover tax obligations connected with exercising vested options. No Rule 10b5-1 plan was reported for the sale, and his direct common-share holdings afterward were 1,539,251.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Matuszewski Jason

(Last)(First)(Middle)
C/O BIOSTEM TECHNOLOGIES, INC.
2836 CENTER PORT CIRCLE

(Street)
POMPANO BEACH FLORIDA 33064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026S(1)14,300D$11,539,251D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A-1 Convertible Preferred Shares(2)05/23/2016 (3)Common Stock100100D
Options (Right to Buy)$2 (4)10/24/2032Common Stock2,000,0002,000,000D
Options (Right to Buy)$10.05 (5)03/17/2035Common Stock198,807198,807D
Options (Right to Buy)$10.05 (6)10/13/2035Common Stock40,42740,427D
Options (Right to Buy)$5.5 (7)02/11/2036Common Stock440,529440,529D
Restricted Stock Units(8) (9) (9)Common Stock33,87433,874D
Restricted Stock Units(8) (10) (10)Common Stock99,90199,901D
Restricted Stock Units(8) (11) (11)Common Stock363,636363,636D
Explanation of Responses:
1. Represents shares sold to cover the Reporting Person's tax obligation in connection with the exercise of vested options to purchase shares of the Issuer's Common Stock.
2. The Series A-1 Preferred Convertible Stock is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Preferred Stock.
3. The Series A-1 Preferred Convertible Stock has no expiration date.
4. These options are fully vested and exercisable.
5. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
6. These options vest according to the following schedule: 33% vested on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
7. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
8. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
9. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
10. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
11. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
/s/ Katherine Gorrell, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading